<u> Cloud-Clone Corp.</u>

RPG302Hu01 100µg Recombinant Absent In Melanoma 2 (AIM2) Organism Species: Homo sapiens (Human) *Instruction manual*

FOR IN VITRO USE AND RESEARCH USE ONLY NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

10th Edition (Revised in Jan, 2014)


[PROPERTIES]

Residues: Met1~Thr343 Tags: Two N-terminal Tags, His-tag and T7-tag Accession: O14862 Host: *E. coli* Subcellular Location: Nucleus. Cytoplasm. Purity: >95% Endotoxin Level: <1.0EU per 1µg (determined by the LAL method). Formulation: Supplied as Iyophilized form in PBS, pH7.4, containing 5% trehalose, 0.01% sarcosyl. Predicted isoelectric point: 9.8 Predicted Molecular Mass: 43.7kDa Applications: SDS-PAGE; WB; ELISA; IP.

(May be suitable for use in other assays to be determined by the end user.)

[<u>USAGE</u>]

Reconstitute in sterile PBS, pH7.2-pH7.4.



Designed by Cloud-Clone Corp., Assembled by Uscn Life Science Inc. ISO9001:2008; ISO13485:2003 11271 Richmond Avenue Suite H104. Houston, TX 77082, USA| Toll free: 001-888-960-7402 | Fax: 001-832-538-0088 | Http://www.cloud-clone.us | E-mail: mail@cloud-clone.us Export Processing Zone Building F, Wuhan. Hubel 430056. PRC | Toll free: 0086-800-880-0687 | Fax: 0086-27-8425-9551 | Http://www.uscnk.com | E-mail: mail@cloud-clone.us

[STORAGE AND STABILITY]

Storage: Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

Stability Test: The thermal stability is described by the loss rate of the target protein. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. (Referring from China Biological Products Standard, which was calculated by the Arrhenius equation.) The loss of this protein is less than 5% within the expiration date under appropriate storage condition.

[<u>SEQUENCES</u>]

The sequence of the target protein is listed below.

MESKYKEILL LTGLDNITDE ELDRFKFFLS DEFNIATGKL HTANRIQVAT LMIQNAGAVS AVMKTIRIFQ KLNYMLLAKR LQEEKEKVDK QYKSVTKPKP LSQAEMSPAA SAAIRNDVAK QRAAPKVSPH VKPEQKQMVA QQESIREGFQ KRCLPVMVLK AKKPFTFETQ EGKQEMFHAT VATEKEFFFV KVFNTLLKDK FIPKRIIIIA RYYRHSGFLE VNSASRVLDA ESDQKVNVPL NIIRKAGETP KINTLQTQPL GTIVNGLFVV QKVTEKKKNI LFDLSDNTGK MEVLGVRNED TMKCKEGDKV RLTFFTLSKN GEKLQLTSGV HSTIKVIKAK KKT